1. Home
  2. KTOS vs RVMDW Comparison

KTOS vs RVMDW Comparison

Compare KTOS & RVMDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KTOS
  • RVMDW
  • Stock Information
  • Founded
  • KTOS 1994
  • RVMDW N/A
  • Country
  • KTOS United States
  • RVMDW United States
  • Employees
  • KTOS N/A
  • RVMDW 490
  • Industry
  • KTOS Military/Government/Technical
  • RVMDW
  • Sector
  • KTOS Industrials
  • RVMDW
  • Exchange
  • KTOS Nasdaq
  • RVMDW Nasdaq
  • Market Cap
  • KTOS N/A
  • RVMDW N/A
  • IPO Year
  • KTOS 1999
  • RVMDW N/A
  • Fundamental
  • Price
  • KTOS $26.24
  • RVMDW $0.38
  • Analyst Decision
  • KTOS Buy
  • RVMDW
  • Analyst Count
  • KTOS 11
  • RVMDW 0
  • Target Price
  • KTOS $25.40
  • RVMDW N/A
  • AVG Volume (30 Days)
  • KTOS 1.2M
  • RVMDW N/A
  • Earning Date
  • KTOS 11-07-2024
  • RVMDW N/A
  • Dividend Yield
  • KTOS N/A
  • RVMDW N/A
  • EPS Growth
  • KTOS N/A
  • RVMDW N/A
  • EPS
  • KTOS 0.10
  • RVMDW N/A
  • Revenue
  • KTOS $1,127,000,000.00
  • RVMDW N/A
  • Revenue This Year
  • KTOS $12.62
  • RVMDW N/A
  • Revenue Next Year
  • KTOS $11.04
  • RVMDW N/A
  • P/E Ratio
  • KTOS $260.99
  • RVMDW N/A
  • Revenue Growth
  • KTOS 11.30
  • RVMDW N/A
  • 52 Week Low
  • KTOS $16.71
  • RVMDW N/A
  • 52 Week High
  • KTOS $28.62
  • RVMDW N/A
  • Technical
  • Relative Strength Index (RSI)
  • KTOS 58.61
  • RVMDW N/A
  • Support Level
  • KTOS $24.34
  • RVMDW N/A
  • Resistance Level
  • KTOS $28.62
  • RVMDW N/A
  • Average True Range (ATR)
  • KTOS 1.07
  • RVMDW 0.00
  • MACD
  • KTOS 0.04
  • RVMDW 0.00
  • Stochastic Oscillator
  • KTOS 59.32
  • RVMDW 0.00

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: